ProsTAV
exploratorybiomarker · high · Mon Jul 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Improve early diagnosis of clinically significant prostate cancer and reduce unnecessary prostate biopsies in patients being evaluated for prostate cancer.
Minimally invasive telomere-associated variable test using HT-Q-FISH/TAT measurements in peripheral blood mononuclear cells, incorporated into risk models for significant prostate cancer.
ClinicalTrials.gov study NCT04124900 was published on 2019-07-15 to demonstrate PROSTAV efficacy in reducing unnecessary biopsies; earlier TAV-based prostate cancer risk models were reported in a 2021 publication.
In a subgroup of 401 patients with PSA 3-10 ng/ml and no prior biopsies, two TAV-based models achieved AUC >= 0.83 in the full cohort and AUC > 0.76 in internal validation; in validation, models would have avoided 33% or 48% of biopsies while losing 0% or 10.3% of significant prostate cancers, respectively.
HealthG
undisclosedconsumer product · low
Provide a health or longevity biomarker product in Life Length's diagnostic pipeline; the supplied material does not define the specific biomarker or use case.
Not specified in the supplied material beyond inclusion in Life Length's biomarker product pipeline.
Listed in the supplied site-analysis pipeline list.
HealthNAD+
undisclosedconsumer product · medium
Measure NAD+ biology as part of Life Length's aging and personalized-medicine biomarker offering.
NAD+ biomarker diagnostic; specific assay method is not detailed in the supplied material.
Listed in the supplied site-analysis pipeline list and described generally as part of Life Length's NAD+ biomarker diagnostics.
HealthOX
undisclosedconsumer product · medium
Measure oxidative-stress biology as part of Life Length's aging and personalized-medicine biomarker offering.
Oxidative-stress biomarker diagnostic; specific assay method is not detailed in the supplied material.
Listed in the supplied site-analysis pipeline list and described generally as part of Life Length's oxidative-stress biomarker diagnostics.
HealthTAV
undisclosedconsumer product · medium
Provide longevity or personalized-medicine assessment using telomere-associated variables.
Telomere-associated biomarker testing based on Life Length's TAT/HT-Q-FISH platform; specific assay details are not provided in the supplied material.
Listed in the supplied site-analysis pipeline list.
PneumoTAV
undisclosedbiomarker · low
Assess disease biology using Life Length's telomere-associated biomarker approach; the supplied material lists PneumoTAV as part of the company's pipeline but does not provide a disease indication or performance claims.
Not specified in the supplied material beyond inclusion in Life Length's telomere/TAT biomarker pipeline.
Listed in the supplied site-analysis pipeline list.
TAT-based telomere contract research services
exploratoryresearch program · medium
Apply Life Length's telomere analytics to external research questions in aging biology, cell quality, tissue biology, and intervention evaluation.
Use proprietary telomere analysis technology / HT-Q-FISH to measure telomere length distributions, percentiles, critically short telomeres, and related telomere variables in human cells.
Recent publications applied the technology to TSOD-treated human fibroblasts and chondrocytes from loose bodies versus intact cartilage.
In TSOD-treated fibroblasts, selected conditions increased median telomere length or 20th percentile and reduced critically short telomeres under oxidative stress. In chondrocytes, loose-body-derived cells had shorter telomere distributions than intact-cartilage cells.
Telomere Analysis Technology (TAT)
undisclosedplatform · high
Quantify telomere distributions and telomere-associated variables at high throughput for aging, disease-risk, clinical, epidemiological, and contract-research applications.
High-throughput quantitative fluorescence in situ hybridization (HT-Q-FISH) with imaging and software workflows that measure telomere-associated variables in cell populations such as PBMCs.
Analytical validation of the TAT HT-Q-FISH platform reported, including comparison with TRF, precision, limits of detection, specificity, reportable range, and reference range.
TAT showed high correlation with TRF for telomere length, assay error of 454 base pairs, limit of detection of 800 base pairs, reportable range lower limit of 4700 bp and upper limit of 14,400 bp, and up to 223 telomere-associated variables from a single sample.
